Impact of physician-pharmacist collaboration on dyslipidemia management in type 2 diabetic patients

Abstract

The objective of this prospective, non-randomized, controlled trial was to determine the impact of physician-pharmacist collaboration on lipid management in diabetic patients at the Bangkok Metropolitan Administration General Hospital compared with usual care. The primary outcome was the achievement rate of LDL-C goal. The secondary outcomes included changes in lipid parameters, changes in usage rate of lipid modifying agents, types and acceptance rates of pharmacist's interventions. One hundred and 108 patients were enrolled into the usual care and the intervention groups, respectively. Baseline demographics and lipid parameters were similar between two groups. At the end of the study, the mean LDL-C was significantly lower in the intervention group (111.8±33 mg/dL vs 124.8 ±37 mg/dL p = 0.008). The proportion of patients who reached the LDL-C target of < 100 mg/dL in the intervention group was significantly higher than those in the usual care group (39.8% vs 25.0% p = 0.023). Beneficial changes in other lipid parameters in favor of the intervention group were also observed. Overall, clinical pharmacists made 60 interventions regarding the modification of lipid lowering therapy, 21 of these were accepted. Sixty interventions on treatment monitoring were made, 32 were accepted by physicians. Significantly more patients in the intervention group received statin therapy. The intensity of statin therapy was also significantly higher in the intervention group. In conclusion, physician-pharmacist collaboration could effectively increase the achievement rate of LDL-C targets in diabetic patients compared with the usual care. The findings of our study support the benefits of multidisciplinary approach in dyslipidemia management.;"การศึกษานี้เป็นการศึกษาแบบไปข้างหน้าเพื่อประเมินผลความร่วมมือระหว่างแพทย์และ เภสัชกรในการรักษาภาวะไขมันผิดปกติในผู้ป่วยเบาหวานชนิดที่ 2 ของผู้ป่วยนอกโรงพยาบาลกลางเปรียบเทียบระหว่างกลุ่มทดลองกับกลุ่มควบคุม ตัวชี้วัดชนิดปฐมภูมิของการศึกษาคือ อัตราที่ผู้ป่วยบรรลุเป้าหมายของ LDL-C ส่วนตัวชี้วัดชนิดทุติยภูม"